Sanofi-Aventis announced plans to restructure its R&D model, set to be completed by 2013.
No layoffs will result from the restructuring, according to the statement (pdf
), although some 1,300 employees will be eligible for “voluntary departures,” according to the Wall Street Journal
. Company locations in the UK, Japan and Spain will be closed, along with four sites in France, with a fifth being divested.
Around 650 people will be shuffled into different locations or jobs in France, according to the statement.
“The objective of this new R&D model is to propose innovate solutions that respond to specific, unmet needs of patients and continue our success in a very competitive international environment, said Chris Viehbacher, CEO, in the statement.